BACKGROUND/AIM: Pemetrexed plus platinum followed by pemetrexed maintenance has been one of the standard first-line treatments in advanced nonsquamous non-small cell lung cancer (NSCLC), but little is known regarding its safety and efficacy for patients with interstitial lung disease (ILD). PATIENTS AND METHODS: The medical records of 24 patients with advanced nonsquamous NSCLC and preexisting ILD who received pemetrexed and platinum doublet therapy with and without pemetrexed maintenance in the first-line setting between December 2009 and June 2016, were retrospectively reviewed. RESULTS: The median progression-free survival time was 4.7 months, and the median overall survival time was 9.5 months. Of the 24 patients analyzed, six received pemetrexed maintenance. Acute exacerbation of ILD (AE-ILD) occurred in five (20.8 %) of 24 patients, including two fatal cases. CONCLUSION: The treatment with pemetrexed plus platinum has a high risk of AE-ILD in patients with advanced nonsquamous NSCLC and preexisting ILD. Copyright
BACKGROUND/AIM: Pemetrexed plus platinum followed by pemetrexed maintenance has been one of the standard first-line treatments in advanced nonsquamous non-small cell lung cancer (NSCLC), but little is known regarding its safety and efficacy for patients with interstitial lung disease (ILD). PATIENTS AND METHODS: The medical records of 24 patients with advanced nonsquamous NSCLC and preexisting ILD who received pemetrexed and platinum doublet therapy with and without pemetrexed maintenance in the first-line setting between December 2009 and June 2016, were retrospectively reviewed. RESULTS: The median progression-free survival time was 4.7 months, and the median overall survival time was 9.5 months. Of the 24 patients analyzed, six received pemetrexed maintenance. Acute exacerbation of ILD (AE-ILD) occurred in five (20.8 %) of 24 patients, including two fatal cases. CONCLUSION: The treatment with pemetrexed plus platinum has a high risk of AE-ILD in patients with advanced nonsquamous NSCLC and preexisting ILD. Copyright
Authors: Harold R Collard; Bethany B Moore; Kevin R Flaherty; Kevin K Brown; Robert J Kaner; Talmadge E King; Joseph A Lasky; James E Loyd; Imre Noth; Mitchell A Olman; Ganesh Raghu; Jesse Roman; Jay H Ryu; David A Zisman; Gary W Hunninghake; Thomas V Colby; Jim J Egan; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Yasuhiro Kondoh; David A Lynch; Joachim Müller-Quernheim; Jeffrey L Myers; Andrew G Nicholson; Moisés Selman; Galen B Toews; Athol U Wells; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2007-06-21 Impact factor: 21.405
Authors: Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Ralph G Zinner; Coleman K Obasaju; David R Spigel; Robert W Weaver; J Thaddeus Beck; David M Waterhouse; Manuel R Modiano; Borys Hrinczenko; Petros G Nikolinakos; Jingyi Liu; Andrew G Koustenis; Katherine B Winfree; Symantha A Melemed; Susan C Guba; Waldo I Ortuzar; Durisala Desaiah; Joseph A Treat; Ramaswamy Govindan; Helen J Ross Journal: J Thorac Oncol Date: 2015-01 Impact factor: 15.609